GMEP regimen in the treatment of refractory or recurrent non-Hodgkin′s lymphoma: a report of its short term effect
- VernacularTitle:GMEP方案治疗难治性或复发性非霍奇金淋巴瘤的近期疗效报告
- Author:
Ouyang XUENONG
;
Wang WENWU
;
Peng YONGHAI
- Publication Type:Journal Article
- Keywords:
lymphoma, non-Hodgkin;
antineoplastic combined chemotherapy-protocols
- From:
Medical Journal of Chinese People's Liberation Army
2001;0(08):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the therapeutic and adverse effects of GMEP regimen in the treatment of refractory or recurrent non-Hodgkin′s lymphoma(NHL). Methods A total of 30 refractory or recurrent NHL patients received a course of GMEP regimen: Gemcitabine (GEM) 1 000mg/m~2, IV, d1, 8; Etoposide (VP16) 60mg/m~2, IV, d1-5; Mitoxatrone (MIT) 6-8mg/m~2, IV, d1; Prednisone(PDN)60mg/m~2, PO, d1-5. The treatment was repeated every 3-4 weeks for 3 courses at least. Results All the 30 patients received a complete course of chemotherapy. Among them 28 (93.3%) were followed-up. The median survival time was 11.3 months. The 1-year and 2-year survival rates were 43.3% and 30.8%, respectively. The total remission rate was 80% (24/30), with CR 20% (6/30) and PR 60% (18/30), and type B symptoms were alleviated in 6 of 10 patients. The main adverse effects were myelotoxicity, nausea and vomiting. Conclusions GMEP regimen can be safely applied to the patients with refractory or recurrent non-Hodgkin′s lymphoma and the short-term response is comparable to the results of other treatment modalities.
